|
gptkbp:instanceOf
|
gptkb:drug
monoclonal antibody fusion protein
|
|
gptkbp:administeredBy
|
ophthalmologist
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
gptkb:FDA
2011
|
|
gptkbp:ATCCode
|
S01LA05
|
|
gptkbp:brand
|
gptkb:Eylea
|
|
gptkbp:CASNumber
|
862111-32-8
|
|
gptkbp:contraindication
|
active intraocular inflammation
ocular infection
|
|
gptkbp:developedBy
|
gptkb:Bayer
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
~7 days (in eye)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
aflibercept
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
VEGF inhibitor
|
|
gptkbp:molecularWeight
|
115 kDa
|
|
gptkbp:monitors
|
gptkb:optical_coherence_tomography
visual acuity testing
|
|
gptkbp:patent
|
gptkb:Bayer
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
intravitreal injection
|
|
gptkbp:sideEffect
|
glaucoma
conjunctival hemorrhage
eye pain
increased intraocular pressure
vitreous detachment
endophthalmitis
retinal detachment
|
|
gptkbp:target
|
gptkb:VEGF-A
gptkb:VEGF-B
gptkb:placental_growth_factor
|
|
gptkbp:UNII
|
48A5M73Z4Q
|
|
gptkbp:usedFor
|
gptkb:diabetic_macular_edema
age-related macular degeneration
diabetic retinopathy
macular edema following retinal vein occlusion
|
|
gptkbp:bfsParent
|
gptkb:F-BVFA
|
|
gptkbp:bfsLayer
|
5
|